lithium perfluorooctane sulfonate | 29457-72-5

• 物质功能分类: 化学试剂 - 有机试剂 - 磺酸盐/亚磺酸盐
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 英文名称: lithium perfluorooctane sulfonate
• 英文别名: lithium;1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonate
• CAS: 29457-72-5
• 化学式: C₈F₁₇O₃S*Li
• 分子量: 506.066
• InChiKey: XVCUGNWRDDNCRD-UHFFFAOYSA-M

物化性质

• 颜色/状态：
  Off-white powder
• 气味：
  Slightly pungent odor
• 熔点：
  Decomposes at 308 °C
• 密度：
  0.56 g/mL (9.6 lbs/gal) (no temperature provided)
• 分解：
  Decomposes at 308 °C. /Technical grade/

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  20

ADMET

毒理性

• 解毒与急救

/SRP:/ 基本治疗：建立专利气道。如有必要，进行吸痰。观察呼吸不足的迹象，并在需要时辅助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，并在必要时进行治疗……监测休克，并在必要时进行治疗……预计癫痫发作，并在必要时进行治疗……对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用生理盐水连续冲洗每只眼睛……不要使用催吐剂。对于摄入，如果患者能吞咽、有强烈的呕吐反射且不流口水，则用水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……在去污后，用干燥的无菌敷料覆盖皮肤烧伤……/毒药A和B/

/SRP:/ Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poison A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 高级治疗：对于无意识、严重肺水肿或呼吸停止的患者，考虑进行口咽或鼻咽气管插管以控制气道。使用球囊阀面罩装置的正压通气技术可能有益。监测心率和必要时治疗心律失常。开始静脉输液，使用5%葡萄糖盐水（D5W）/SRP: "保持开放"，最小流量/。如果出现低血容量的迹象，使用乳酸钠林格液。注意液体过载的迹象。考虑使用药物治疗肺水肿。对于伴有低血容量迹象的低血压，谨慎输液。注意液体过载的迹象。使用地西泮（安定）治疗癫痫。使用丙美卡因氢氯化物协助眼部冲洗。/毒药A和B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poison A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

实验动物：亚慢性或前慢性暴露/ 每组十只雄性大鼠通过饮用水口服给予0、0.3、1.0或3.0 mg/kg/天的/锂全氟辛烷磺酸盐/（LPOS）（纯度：96.87%）90天。每组十只雌性大鼠同样以0、0.02、0.06或0.20 mg/kg/天的测试物质处理90天。当高剂量雌性未表现出任何与治疗相关的影响时，又进行了另一项研究，每组十只雌性以0或0.60 mg/kg/天的测试物质处理91天。治疗未导致死亡或临床体征。在治疗13周后，高剂量雄性和雌性组的平均体重分别为对照组的87.5%（p<0.05）和90.6%。雄性红细胞计数、血红蛋白和血容量的平均值以剂量相关的方式受到影响，1.0和3.0 mg/kg/天组的平均值较低（p<0.05）。同样，雌性在0.6 mg/kg/天时的平均红细胞计数和血容量也较低（p<0.05）。对于雄性，3.0 mg/kg/天组的血清总胆红素平均值升高（p<0.05）。相比之下，血清胆固醇和甘油三酯水平以剂量相关的方式降低，1.0 mg/kg/天组的胆固醇（p<0.05）和0.3 mg/kg/天组的甘油三酯有显著性。1.0和3.0 mg/kg/天组的平均血尿素氮增加（p<0.05）。平均绝对肝重和相对肝重以治疗相关的方式增加，1.0和3.0 mg/kg/天组有显著性（p<0.05）。3.0 mg/kg/天组的平均相对肾脏和睾丸重量增加。3.0 mg/kg/天处理组肝脏的组织病理学检查显示肝细胞空泡化的发生率和严重程度增加。目标器官：肝脏和血液参数。未表明有害作用。NOEL：（雄性）<0.3 mg/kg/天（基于0.3 mg/kg/天处理组血清甘油三酯的减少），（雌性）0.2 mg/kg/天（基于0.6 mg/kg/天处理组较低的红细胞计数和血容量以及更大的平均肝重）。

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Ten male rats/group were dosed orally in the drinking water with 0, 0.3, 1.0 or 3.0 mg/kg/day of /Lithium perfluorooctane sulfonate/ (LPOS) (purity: 96.87%) for 90 days. Ten female rats/group were likewise treated with 0, 0.02, 0.06 or 0.20 mg/kg/day of the test material for 90 days. When the high dose females failed to demonstrate any treatment-related effects, an additional study was instituted with ten females/group treated with 0 or 0.60 mg/kg/day of the test material for 91 days. No mortality nor clinical signs resulted from the treatment. The mean body weights for the respective high dose male and female groups were 87.5 (p<0.05) and 90.6% of those of the control after 13 weeks of treatment. Mean values for red blood cell counts, hemoglobin and hematocrit for the males were affected in a dose-related manner with lower mean values noted for both 1.0 and 3.0 mg/kg/day groups (p<0.05). Similarly, the mean rbc count and hematocrit were lower for the females at 0.6 mg/kg/day (p<0.05). For the males, mean serum total bilirubin was elevated in the 3.0 mg/kg/day group (p<0.05). In contrast, the mean serum cholesterol and triglyceride levels were decreased in a dose-related manner, with significance (p<0.05) noted for cholesterol in the 1.0 mg/kg/day group and triglycerides in the 0.3 mg/kg/day group. The mean blood urea nitrogen was increased in the 1.0 and 3.0 mg/kg/day groups (p<0.05). The mean absolute liver and relative liver weights were increased in a treatment-related manner with significance (p<0.05) noted for the 1.0 and 3.0 mg/kg/day groups. The mean relative kidney and testes weights were increased in the 3.0 mg/kg/day group. Histopathologic examination of the livers in the 3.0 mg/kg/day treatment group revealed an increased incidence and severity of hepatocytic vacuolation. Target Organ: liver and blood parameters. No adverse effect indicated. NOEL: (M) <0.3 mg/kg/day (based upon the reduction of serum triglycerides in the 0.3 mg/kg/day treatment group), (F) 0.2 mg/kg/day (based upon the lower rbc count and hematocrit and greater mean liver weight in the 0.6 mg/kg/day treatment group).

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

实验动物：发育或生殖毒性/ 在兔子的发育研究中，母体毒性在1 mg/kg/天的剂量及以上被观察到，基于给药期间体重增加减少，随后在给药后体重增加出现反弹。在所测试的最高剂量4 mg/kg/天时观察到发育毒性。影响包括胎儿致死性、骨骼变异（未骨化的颅骨、胸骨、距骨、耻骨和额外完整的肋骨）以及胎儿体重减少。没有建立母体无观察到有害作用水平（NOAEL），基于体重增加减少，母体的最低观察到有害作用水平（LOAEL）为1 mg/kg/天。发育毒性NOAEL为2 mg/kg/天。在大鼠发育研究中，母体毒性在6 mg/kg/天的剂量下被观察到，基于平均体重、平均体重增加、食物消耗和临床体征（蜷缩和一只动物粪便减少）的减少。母体NOAEL为3 mg/kg/天。发育毒性NOAEL为6 mg/kg/天，LOAEL为12 mg/kg/天，基于胎儿致死性增加、胎儿体重减少、外部和软组织畸形以及骨骼变异。

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ In the developmental study in rabbits, maternal toxicity was observed at 1 mg/kg/day and above, based on reduced body weight gains during the dosing period, followed by a rebound in body weight gains post-dosing. Developmental toxicity was observed at the highest dose tested, 4 mg/kg/day. Effects included feto-lethality, skeletal variations (unossified skull bones, sternebrae, talus, pubis and extra full rib) and decreased fetal body weights. A maternal NOAEL was not established and the maternal LOAEL was 1 mg/kg/day, based on reduced body weight gains. The developmental NOAEL was 2 mg/kg/day. In the rat developmental study, maternal toxicity was observed at 6 mg/kg/day based on reductions in mean body weights, mean body weight gains, food consumption and clinical signs (hunched and few feces in one animal). The maternal NOAEL is 3 mg/kg/day. The developmental NOAEL is 6 mg/kg/day and the LOAEL is 12 mg/kg/day based on increased fetolethality, lower fetal body weights, external and soft tissue malformations, and skeletal variations.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

实验室动物：发育或生殖毒性/每组24或25只交配的Crl:CD大鼠通过口服灌胃方式接受0、3、6或12 mg/kg/天的/锂全氟辛烷磺酸盐/(LPOS)（纯度：96%）（批号：101）处理，从妊娠第6天到第15天。高剂量组中的4只雌性大鼠在妊娠第17天或19天处于极度痛苦中被安乐死。该组中的另一只雌性大鼠在第18天被发现死亡。高剂量动物出现了弓背姿势、躺卧和会阴部染色的临床体征。此外，死亡动物之一在出现强直和弛缓性身体震颤和惊厥。6和12 mg/kg/天组的平均体重增加较低（p<0.01），在整个处理期间。同样，这两个组在处理期间的平均每日食物消耗量也较低（p<0.01）。此外，3 mg/kg/天处理组的平均每日食物消耗量在妊娠第12天至第16天低于对照组（p<0.01）。高剂量组发生了晚期吸收和胎儿死亡。12 mg/kg/天处理组的平均胎儿体重低于对照组（p<0.01）。高剂量组出现了腭裂（84/107）、水肿（93/259）以及未骨化骨骼的发生率增加。... 母体NOEL：< 3 mg/kg/天（基于3 mg/kg/天组食物消耗量减少），发育NOEL：6 mg/kg/天（基于12 mg/kg/天处理组胎儿平均体重降低和晚期吸收、胎儿死亡、腭裂和胎儿水肿的发生率）。

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Twenty four or 25 mated female Crl:CD rats/group were treated by oral gavage with 0, 3, 6, or 12 mg/kg/day of /Lithium perfluorooctane sulfonate/ (LPOS) (purity: 96%) (lot no. 101) from day 6 through day 15 of gestation. Four of the females in the high dose group were euthanized in extremis on gestation days 17 or 19. Another female in that group was found dead on day 18. Clinical signs of hunched posture, recumbency and staining of the anogenital region were noted for the high dose animals. In addition, one of the animals which died displayed tremors and convulsions with rigid and flaccid body tone. Lower mean body weight gain was demonstrated by both the 6 and 12 mg/kg/day groups (p<0.01) over the course of the treatment period. Likewise, mean daily food consumption was lower for these two groups during the treatment period (p<0.01). In addition, the mean daily food consumption for the 3 mg/kg/day treatment group was lower than that of the control from days 12 to 16 of gestation (p<0.01). Late resorptions and fetal death occurred in the high dose group. The mean fetal weight of the 12 mg/kg/day treatment group was lower than that of the control group (p<0.01). The high dose group suffered from cleft palate (84/107), and edema (93/259) as well as an increased incidence of unossified bones. ... Maternal NOEL: < 3 mg/kg/day (based upon reduced food consumption by the 3 mg/kg/day group), Developmental NOEL: 6 mg/kg/day (based upon lower mean fetal weight and incidence of late resorptions, fetal death, cleft palate and edema in the fetuses of the 12 mg/kg/day treatment group)

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36,S36/37,S45,S53,S61
• 危险类别码：
  R36/37/38
• RTECS号：
  RG9701750

反应信息

• 作为反应物：
  描述：

  decamethylferrocenium nitrate 、 lithium perfluorooctane sulfonate 以 水 为溶剂， 以54%的产率得到
  参考文献：
  名称：

  十甲基二茂铁鎓盐与全氟烷基磺酸盐和-羧酸盐阴离子的相变和热性质表现出无序性

  摘要：

  十甲基二茂铁鎓盐与全氟烷基磺酸根阴离子（C。ñF。2个ñ+1个所以第三名--; n  = 1、4和8）和全氟烷基羧酸根阴离子（C。ñF。2个ñ+1个一氧化碳2个--; n  = 1-4）用于研究阴离子对盐的热行为的影响。差示扫描量热法（DSC）测量表明，所有盐在固态下均表现出相变。具有八甲基二茂铁鎓阳离子或十甲基钴co鎓阳离子的盐表现出与相应的十甲基二茂铁鎓盐不同的相序。用结晶学方法研究了两种盐与相变有关的结构变化。[Fe（C 5 Me 5）2 ]（CF 3 SO 3）在-121.6°C时伴随着阳离子构象以不同比例排列为偏影和交错构象的顺序。在低温阶段，单位晶胞体积变大六倍，并且空间群从P mn2 1变为P 1。[Fe（C 5 Me 5）2 ]（C 3 F 7 CO 2）在-115°C时的相变不伴随晶胞或空间群（P 2 1 / c）。在低温相中，存在于高温相中的阴离子的释放或位移被抑制，这

  DOI：

  10.1016/j.jorganchem.2012.04.005
• 作为产物：
  描述：

  全氟辛基磺酰氟 、 lithium trimethylsilanolate 以 四氢呋喃 为溶剂， 以The product, lithium perfluorooctanesulfonate (6.6 g, 55% yield), was isolated as a white solid的产率得到lithium perfluorooctane sulfonate
  参考文献：
  名称：

  Preparation of anhydrous organic acid salts

  摘要：

  通过接触和反应有机或聚合酸氟化物、酸酐或酯和有机碱或碱土金属硅醇盐，制备无水有机酸碱或碱土金属盐的一步法。

  公开号：

  US04723016A1
• 作为试剂：
  描述：

  反-1-甲氧基-3-(三甲基硅氧基)-1,3-丁二烯 、 (4-nitro-benzylidene)-phenyl-amine 在 lithium perfluorooctane sulfonate 作用下， 以 various solvent(s) 为溶剂， 50.0 ℃ 、9.0 MPa 条件下， 反应 10.0h， 以80%的产率得到2-(4-硝基苯基)-1-苯基-2,3-二氢吡啶-4-酮
  参考文献：
  名称：

  Lithium heptadecafluorooctanesulfonate catalyzed Mannich-type and aza-Diels–Alder reactions in supercritical carbon dioxide

  摘要：

  The Mannich-type reaction of imines with (1-methoxy-2-methylpropenyloxy)trimethylsilane and aza-Diels-Alder reaction of imines with Danishefsky's diene can be carried out in scCO(2) in the presence of lithium heptadecafluorooctanesulfonate which offer a way to synthesize beta-amino carbonyl compounds and nitrogen-containing six-membered ring compounds under environmentally benign conditions. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2004.05.065

文献信息

• [EN] FLUORINATED IONIC LIQUIDS WITH HIGH OXYGEN SOLUBILITY FOR METAL-AIR BATTERIES<br/>[FR] LIQUIDES IONIQUES FLUORÉS À FORTE SOLUBILITÉ DANS L'OXYGÈNE POUR BATTERIES MÉTAL-AIR
  申请人：TOYOTA MOTOR EUROPE

  公开号：WO2018033200A1

  公开（公告）日：2018-02-22

  The present invention relates to ionic compounds containing an anion, and a cation having the following structural formula (1): R1R2R3N+-(|inker1)-O-(iinker2)-(FC) wherein: - R1 and R2 either linear or branched alkyl groups or together form a N-heterocylic ring with the nitrogen atom to which they are joined;- R3 is linear or branched alkyl group; - linker1 and linker2 are alkylene chains or polyether chains; and - the group FC is a fluorinated alkyl group, as well as an electrolyte material comprising such an ionic compound and a metal salt, and metal-air batteries using such an electrolyte material. The invention also relates to a metal-air battery containing an electrolyte material, wherein the electrolyte material comprises at least one ionic compound and a metal salt, and wherein at least one ionic compound contains an anion CnF2n+1COO- or CnF2n+1S03-, where in each case n is at least 1 and at most 10.

  本发明涉及一种含有阴离子和具有以下结构式（1）的阳离子的离子化合物：R1R2R3N+-(|inker1)-O-(iinker2)-(FC)其中：- R1和R2可以是线性或支链烷基，也可以共同形成与它们连接的氮原子的N-杂环环；- R3是线性或支链烷基；- linker1和linker2是烷基链或聚醚链；- FC是含氟烷基。此外，本发明还涉及一种包含这样的离子化合物和金属盐的电解质材料，以及使用这种电解质材料的金属-空气电池。本发明还涉及一种金属-空气电池，其中电解质材料包含至少一种离子化合物和金属盐，其中至少一种离子化合物包含CnF2n+1COO-或CnF2n+1S03-的阴离子，其中n分别为至少1且最多为10。
• Curable composition
  申请人：Tamai Hitoshi

  公开号：US20060173121A1

  公开（公告）日：2006-08-03

  The present invention provides a curable composition which comprises: Component (A): A polyoxyalkylene polymer containing at least one reactive silyl group at a molecular chain terminus; Component (B): A polymer composed of acrylic acid alkyl ester monomer units and/or methacrylic acid alkyl ester monomer units containing, on the average, at least one reactive silyl group in each molecule; and, Component (C): An ionic surfactant, and which may be suitably used as a sealant for buildings inhibiting dust/dirt adhesion and hardly allowing traces of rain and like stains to leave thereon.

  本发明提供了一种可固化的组合物，其包括：组分（A）：聚氧烷基聚合物，其在分子链末端含有至少一个反应性硅基团；组分（B）：由丙烯酸烷基酯单体单元和/或甲基丙烯酸烷基酯单体单元组成的聚合物，每个分子平均含有至少一个反应性硅基团；以及组分（C）：一种离子表面活性剂，可用作建筑密封剂，抑制灰尘/污垢附着，几乎不留下雨水等污渍的痕迹。
• PROCESS FOR PRODUCTION OF B-LACTAM COMPOUND
  申请人：Watanabe Shoji

  公开号：US20100292463A1

  公开（公告）日：2010-11-18

  Disclosed is a process for producing a carbapenem compound represented by Formula [1], which is characterized by allowing a base and a Lewis acid metal salt to coexist in the reaction of a compound represented by Formula [2] with a compound represented by Formula [3]. According to the process, a side-chain mercaptothiazole can be introduced into a β-lactam skeleton efficiently in the production of a β-lactam compound having an excellent antibacterial activity against a Gram-positive bacterium. [3] [2] [1] wherein R 1 represents a lower alkyl group or the like; R 2 represents hydrogen atom or the like; R 3 represents a protective group for a carboxyl group; L represents an active ester of a hydroxy group; R 4 represents hydrogen atom or the like; and R 5 represents hydrogen atom or the like.

  本发明公开了一种制备由公式[1]表示的碳青霉烯化合物的过程，其特征在于在公式[2]表示的化合物与公式[3]表示的化合物的反应中，允许碱和路易斯酸金属盐共存。根据该过程，在生产对革兰氏阳性菌具有优异抗菌活性的β-内酰胺化合物时，可以高效地将侧链巯基噻唑引入β-内酰胺骨架中。[3] [2] [1] 其中R1表示较低的烷基或类似物；R2表示氢原子或类似物；R3表示羧基的保护基；L表示羟基的活性酯基；R4表示氢原子或类似物；R5表示氢原子或类似物。
• High concentration topical insecticides containing pyrethroids
  申请人：Cottrell W. Ian

  公开号：US20050009881A1

  公开（公告）日：2005-01-13

  A topical insecticide preparation is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The topical insecticide contains a combination of a first pyrethroid insecticide effective for killing fleas, a second pyrethroid insecticide effective for killing ticks, and an insect growth regulator (IGR). The topical insecticide preparation can be packaged together or packaged so that the first and second pyrethroid insecticides are stored separately prior to administration of the insecticide preparation to the animal. The combination of the first and second pyrethroid insecticides with an insect growth regulator results in an insecticide preparation formulated to have enhanced insecticidal activity against fleas and ticks compared to the effectiveness of the first and second insecticides used alone. Further, the combination of the first and second pyrethroid insecticides with an insect growth regulator produces an insecticide preparation having enhanced insecticidal activity against fleas and ticks while advantageously minimizing the total amount of insecticide needed for its effectiveness.

  提供了一种局部杀虫剂制剂，可以安全使用并避免常见的传统局部杀虫剂的许多有害副作用。该局部杀虫剂包含第一个对杀灭跳蚤有效的拟除虫菊酯杀虫剂，第二个对杀灭蜱有效的拟除虫菊酯杀虫剂和昆虫生长调节剂（IGR）。该局部杀虫剂制剂可以一起包装或分开包装，以便在将杀虫剂制剂施用于动物之前分别储存第一个和第二个拟除虫菊酯杀虫剂。第一个和第二个拟除虫菊酯杀虫剂与昆虫生长调节剂的组合使得该杀虫剂制剂相对于单独使用第一个和第二个杀虫剂具有增强的杀虫活性。此外，第一个和第二个拟除虫菊酯杀虫剂与昆虫生长调节剂的组合在优化减少杀虫剂总量的同时，具有增强的杀虫活性，可以有效杀灭跳蚤和蜱。
• HIGH CONCENTRATION TOPICAL INSECTICIES CONTAINING PYRETHROIDS
  申请人：Cottrell Ian

  公开号：US20070276014A1

  公开（公告）日：2007-11-29

  A topical insecticide preparation is provided which can be safe to use and avoids many common deleterious side effects of conventional topical insecticides. The topical insecticide contains a combination of a first pyrethroid insecticide effective for killing fleas, a second pyrethroid insecticide effective for killing ticks, and an insect growth regulator (IGR). The topical insecticide preparation can be packaged together or packaged so that the first and second pyrethroid insecticides are stored separately prior to administration of the insecticide preparation to the animal. The combination of the first and second pyrethroid insecticides with an insect growth regulator results in an insecticide preparation formulated to have enhanced insecticidal activity against fleas and ticks compared to the effectiveness of the first and second insecticides used alone. Further, the combination of the first and second pyrethroid insecticides with an insect growth regulator produces an insecticide preparation having enhanced insecticidal activity against fleas and ticks while advantageously minimizing the total amount of insecticide needed for its effectiveness.

  提供了一种局部杀虫剂制剂，可以安全使用，并避免许多传统局部杀虫剂的常见有害副作用。该局部杀虫剂包含第一种杀灭跳蚤有效的拟除虫菊酯杀虫剂，第二种杀灭蜱有效的拟除虫菊酯杀虫剂和昆虫生长调节剂（IGR）。该局部杀虫剂制剂可以一起包装或分开包装，以便在给动物施用杀虫剂制剂之前分别存储第一和第二种拟除虫菊酯杀虫剂。第一和第二种拟除虫菊酯杀虫剂与昆虫生长调节剂的组合导致杀虫剂制剂具有比单独使用第一和第二种杀虫剂更强的杀虫活性，可以增强对跳蚤和蜱的杀虫活性。此外，第一和第二种拟除虫菊酯杀虫剂与昆虫生长调节剂的组合产生的杀虫剂制剂在优化杀虫效果的同时，有利于最小化所需杀虫剂的总量。